Thomas A. Ritchie, M.D., FACC
Cardiology, Cardiovascular Disease
Dr. Thomas A. Ritchie is Board Certified in Cardiovascular Disease, Nuclear Cardiology, and Internal Medicine. He completed his Fellowship in Cardiology and Residency in Internal Medicine through Emory University Affiliated Hospitals. Prior to earning his Doctorate of Medicine from Emory University, Dr. Ritchie graduated Cum Laude from the University of Georgia with a Bachelor of Science in Microbiology. Dr. Ritchie is a Fellow of the American College of Cardiology.
Medical School - Emory University School of Medicine, Alanta, GA
Internship - Emory University Hospital, Atlanta, GA
Residency - Emory University Affiliated Hospitals, Altanta, GA
Fellowship - Emory University Affiliated Hospitals, Atlanta, GA
- Phoenix magazine’s “Top Docs” in Cardiology in 2006, 2007, 2008, 2010, 2015.
- Elected by his peers for inclusion in Best Doctors in America 2005-2016.
- Alpha Omega Alpha National Honor Medical Society – Emory University School of Medicine.
- Phi Beta Kappa – University of Georgia.
- Press Ganey, a renowned research firm, ranks him in the top 10th percentile of physicians in the country whose patients would recommend him as a physician to friends and family.
- 2000 to Current: SPORTIF V – An Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Embolic Events in patients with Atrial Fibrillation. Sub-Investigator.
- 1999 to Current: VALIANT Trial – Valsartan In Acute Myocardial Infarction Trial. A multinational, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high risk patients after myocardial infarction. Sponsored by Novartis Pharmaceuticals Corporation. Sub-Investigator.
- 1999 to Current: GUSTO IV AMI Trial – A Phase III Randomized, Open-Label Trial Evaluating The Efficacy And Safety Of ReoPro7 (Abciximab) In Combination With Reduced Dose Retavase7/RapilysinJ (Recombinant Plasminogen Activator, Reteplase, r-PA) For The Treatment Of Acute Myocardial Infarction. Sub-Investigator.
- 1996: “Pulmonary Hypertension in Patients with Dilated Cardiomyopathy” under Andrew Smith, M.D. Emory University.
- 1986: “Characterization of a Plasmid as a Cloning Vector” under William Finnerty, Ph.D.University of Georgia.
- 1988: “Evaluation of a Hospital’s Quality Assurance Program: Impact on Patient Care” under Joe Boone, Ph.D. Centers for Disease Control.
- 1992: CNN Healthweek Program Interview.
- 1993: “Myocardial Infarction due to Pheochromocytoma” Associates Scientific Sessions American College of Physicians.